Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 16/20 | 0.63 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.62 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3106436 | 0.90 | AKR1C3 (0.61) | HRH4AKR1C3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL13173670 | 0.90 | HRH4 (0.64) | HRH4AKR1C3 | |
| SCHEMBL11981526 | 0.84 | AKR1C3 (0.64) | HRH4AKR1C3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL3109604 | 0.83 | AKR1C3 (0.78) | HRH4AKR1C3 | |
| SCHEMBL13174701 | 0.82 | AKR1C3 (0.71) | AKR1C3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13174674 | 0.81 | AKR1C3 (0.63) | HRH4AKR1C3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL13175473 | 0.81 | AKR1C3 (0.62) | HRH4AKR1C3 | |
| SCHEMBL13174668 | 0.80 | AKR1C3 (0.74) | HRH4AKR1C3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL13175717 | 0.80 | AKR1C3 (0.61) | HRH4AKR1C3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL13173652 | 0.79 | AKR1C3 (0.73) | HRH4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513422-B2 | Piperidine derivative | ASTELLAS PHARMA INC. (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8513422-B2 | Piperidine derivative | ASTELLAS PHARMA INC. (JP) | 2013-08-20 | — | — | US | disclosed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2181990-A1 | PIPERIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | AR, NR5A1, CYP17A1 | HRH4 481/4885AKR1C3 72/4885GRIN2D 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.